This is a comment on" Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants." Vaccine. 2019 May 21; 37 (23): 2990. This is a comment on" A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

Niraj Rathi, Sajjad Desai , Anand Kawade , Padmasani Venkatramanan , Ritabrata Kundu , Sanjay K Lalwani , AP Dubey , D Narayanappa , R Ghildiyal , NJ Gogtay , P Venugopal , S Palkar , R Munshi , G Kang , S Babji , A Bavdekar , S Juvekar , N Ganguly , P Niyogi , KG Uttam , HS Rajani , A Kondekar , D Kumbhar , S Mohanlal , MC Agarwal , P Shetty , K Antony , B Gunale , A Dharmadhikari , Y Tang , PS Kulkarni , and J Flores. "Response to: Letter from P. Gillard and B. Benninghoff.." Vaccine 37, no. 23 (2019): 2991-2992.